Key Takeaways
- Steady quarter, guidance held: India adjusted growth of 9% YoY and US respiratory momentum offset cost headwinds, letting management reaffirm the full-year 21%–22% EBITDA margin band.
- The H2 launch slate is the thesis: Three significant complex US launches, including generic Advair and Abraxane, are expected in H2 and are already factored into the margin guidance.
- Peptide portfolio is scaling, not sprinting: The first peptide product is on track for teens market share by year-end, with two more launches likely late next year, each targeting a $35–50 mn opportunity if executed well.
- Cost pressure is persistent, not peaking: Freight and procurement cost increases are expected to continue, and R&D spend will rise through the year to 5.5%–6% of revenue, making the H2 launch-dependent margin recovery a live variable.
- What to watch next quarter: Whether the Goa plant secures an FDA inspection date, the pace of R&D spend ramp-up, and any signal on the exact timing of the Advair and Abraxane launches.
US Business & Complex Pipeline
- Base portfolio steady: The US business delivered sustainable growth with modest price erosion on the overall portfolio, while the DTM respiratory franchise grew 22% YoY to reach a top-three rank in generic respiratory market share.
- Albuterol erosion gradual: Incremental price erosion occurs each quarter but is not deep-discount erosion, and management had not compared whether Q1 erosion was higher or lower than the prior quarter’s trend.
- US profitability in line: Current US profitability is at the company average; when new launches happen, it will remain in line with the company average, not above it.
- Three significant H2 launches: Complex launches expected in H2 include Advair (hoped for earlier part of H2), Abraxane (latter part of H2, pending an FDA inspection where most items have been addressed), and generic Revlimid (launch when the market forms per the settlement agreement, no exact date given).
- Peptide portfolio build-out: Five peptide products in the pipeline; the first is scaling as planned toward teens market share by year-end, one likely launches late this year or early next, and two more probably launch late next year. Cipla is not first to market in any of the first few, with 2–3 players expected in each market.
- Partnered inhalation asset delayed: The partner had to do additional work and resubmitted after the agency was not completely satisfied with earlier responses; the market stays relevant with no generic entrant yet.
Vohra: "I think the market is fairly large for any peptide for the one that are there I think will not be uncommon to see your product in the $35-50 million range, if executed well."
India Business
- Core portfolio strength: One-India growth of 9% YoY adjusted for COVID portfolio normalization was driven by flagship brand equity across key chronic therapies, in-clinic excellence, and digital engagement. Growth was roughly 50% volume-led and 50% price-led.
- Trade generics bullish: Management is very bullish on trade generics, which continues to grow significantly higher than the market, historically at the same level as branded business or marginally higher.
- Industry outlook: Cipla expects to continue growing higher than the industry; the core base business (ex-COVID) for the market should grow about 10% for the full year.
- Diabetes portfolio flexibility: If potential for a particular category or class is diminished, Cipla will have conversations with the branded company to either return the asset or continue selling with modifications, keeping the objective of staying relevant and competitive.
- GoApptiv investment: Incremental investment planned to widen adoption of end-to-end brand marketing and channel engagement for year 2–6 towns.
Vohra: "We are very bullish about this market specially as healthcare deepens in India... we continue to grow significantly higher than market in the trade generic category..."
Margins & Cost Structure
- Gross margin held: At 62.3%, broadly in line with last year, as a 170 bps impact from higher procurement, freight, and forex was offset by calibrated price hikes and the benefit of decline in the low-margin COVID portfolio.
- Expense discipline: Total expenses declined 6.6% sequentially, with other expenses down 15% due to lower R&D spends and judicious promotional and growth-linked investments. Employee costs rose 7% YoY driven by increments.
- Cost pressure to persist: Freight cost and procurement cost increases are expected to continue for some period of time; new launches are expected to compensate for the increase.
- R&D spend trajectory: R&D costs were lower in Q1 but are expected to increase in coming quarters as clinical trials enroll more patients, peaking in Q2, Q3, and Q4, with full-year spend closer to 5.5%–6% of revenue.
- Margin guidance logic: The 21%–22% EBITDA margin guidance is maintained; Revlimid and Advair launches are factored in, and management noted the guidance does not mean they will hold to making sure they are within the range if business mix allows otherwise.
Jain: "The freight cost and other procurement cost related increase, we expect it to continue for some period of time so therefore we want to... give guidance in this range only."
Other Businesses & Geographies
| Segment | Trend | Commentary |
|---|---|---|
| Global Consumer | ▲ Strong traction | Contribution now 9% of overall Cipla revenue; Consumer Health business is now EBITDA positive. |
| SAGA region | ▼ Declined 10% YoY ($) | South Africa Private business had muted primary sales expected to recover in coming quarters; secondary demand continues with Cipla outperforming the industry. |
| International Markets | ▲ Grew 18% YoY ($) | Included benefit of last year’s low base from timing deferrals for Middle Eastern supplies; DTM franchise delivered strong double-digit growth offsetting forex volatility and muted B2B demand. |
| API business | ▬ Normalized | Last year included a profit share on commercial supply of an API to a partner, recognized in the previous year’s quarter. |
- Core operating profitability: Grew 12% after adjusting for COVID portfolio normalization and the API profit share in last year’s base.
- Acquisition: Acquired Endura Mass in July 2022 to boost wellness portfolio and diversify into the nutrient category.
- Achira Labs investment: Announced investment to propel Cipla’s entry into point-of-care diagnostics and the AMR space through microfluidics-based technologies.
Regulatory & Pipeline Updates
- Indore inspection: Routine preapproval inspection for an ANDA filed from the site resulted in two minor observations; Cipla has responded to the FDA.
- Goa plant: Continuing to work with US FDA on inspection timelines; no date given.
- Advair: Cipla has responded to agency queries; the inspection is also related to the Advair program; no currently pending queries that management is aware of.
- Abraxane: An FDA inspection is critical and hoped for soon; most items on the product have been addressed.
- Biosimilars: One respiratory biosimilar asset progressing between Kemwell and Cipla with a launch timeline 5–6 years out; Cipla is also developing products for the India biosimilar franchise, and a second product for the US is under discussion.
- Partnered product economics: For products manufactured at Cipla’s facility and partnered in development, the daily economics are better than a purely in-licensed product, but actual numbers vary by product and are not divulged. For partnered peptides where manufacturing is at the partner, Cipla buys the product so cost flows into gross margin; R&D is charged off and milestones are amortized over the usual life of the asset.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin | Maintain 21%–22% range for FY23; freight and procurement cost increases expected to continue, offset by new launches | FY23 |
| R&D spend | Closer to 5.5%–6% of revenue for the full year, increasing as clinical trials enroll more patients | FY23 |
| US complex launches | Three significant launches expected: Advair (earlier part of H2), Abraxane (latter part of H2, pending FDA inspection), Revlimid (when market forms per settlement) | H2 FY23 |
| Peptide portfolio | First product to reach teens market share by year-end; one more launch late this year or early next; two more probably late next year | FY23–FY24 |
| India business | Continue to grow higher than the industry; core base market expected to grow about 10% for the full year | FY23 |
| South Africa Private | Muted primary sales expected to recover | Coming quarters |
| Consumer Health | Grown sustainably | Coming quarters |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Revenue | Not explicitly stated as a consolidated figure |
| Reported EBITDA | ₹1,143 cr, 21.3% of sales |
| Reported EBITDA margin | 21.3%, tracking in line with full-year guidance of 21%–22% |
| Core operating profitability growth | 12%, adjusted for COVID portfolio normalization and API profit share in last year's base |
| Profit after tax | ₹686 cr, 12.8% of revenue |
| Effective tax rate | 27.5% |
| Gross margin after material cost | 62.3%, broadly in line with last year; absorbed 170 bps impact from higher procurement, freight and forex |
| Total expenses (employee + other) | ₹2,207 cr, declining 6.6% sequentially |
| Employee costs | ₹956 cr, up 7% YoY, driven by increments |
| Other expenses (R&D, regulatory, quality, manufacturing, sales promotion) | ₹1,252 cr, declining 15% sequentially |
| Total R&D spend | ₹274 cr, 5.1% of revenue; full-year guidance of 5.5%–6% |
| One-India business growth (ex-COVID) | 9% YoY, adjusted for COVID portfolio normalization |
| Global Consumer franchise contribution | 9% of overall Cipla revenue |
| Cipla Health annualized franchise (incl. Endura Mass) | ₹600 cr, well poised to achieve |
| US core formulation sales | $155 million, growth of 10% YoY |
| DTM Respiratory Franchise growth | 22% over last year |
| Generic respiratory market share rank | Top three in the US |
| SAGA region growth | Declined 10% YoY in dollar terms |
| South Africa private market share | 7.4%, third position; grew 10.6% vs 7% overall market per IQVIA MAT May 2022 |
| International market business growth | 18% YoY in dollar terms |
| Long-term debt | ZAR 72 cr in South Africa, $7 million in Uganda |
| Working capital loans | $49 million, €3 million, GBP 3 million and others |
| Other income | ₹106 cr, higher QoQ due to exchange gain and slightly higher financing income |
| EBITDA margin adjusted for 170 bps cost impact | 23% (per an analyst's math) |